Abstract
Background: 21 gene recurrence score (RS) testing is routinely used to help decide management of early, hormone receptor positive, HER2 negative breast cancer without nodal spread. Recent data from Kalinsky et al (2021) has suggested value from RS testing in the management of patients with node positive disease, permitting postmenopausal women with stage N1 disease and a RS 0–25 to avoid toxic adjuvant chemotherapy safely.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
